A Phase 4 interventional study of Olanzapine in Bipolar Disorder, sponsored by Eli Lilly and Company. Completed at 11 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2006-07-25.
Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing olanzapine in Bipolar Disorder — none open to participants now, none under way, none of them phase 3. Olanzapine · Bipolar Disorder.
Among the 28 studies testing olanzapine in Bipolar Disorder, this one is the 7th largest by enrollment, is one of 5 that started in 2004, is one of 19 in phase 4, and was the 8th registered.
1,685 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →None of the 28 studies testing olanzapine in Bipolar Disorder is open now. The open studies under Bipolar Disorder, anywhere →
Olanzapine: first FDA approval 1996 (ZYPREXA), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 208 Bipolar Disorder studies recruiting now, 59 (28%) set no upper age limit and 136 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 5 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 180 is above the median of 64 across 1,280 interventional studies indexed under Bipolar Disorder.
Median enrollment 120 across the 28 interventional studies. Of the 27 that completed or were terminated, 8 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
15 of 28 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
20 studies in Bipolar Disorder by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 19 finished, 5 (26%) have results posted.
Among the 20 studies in Bipolar Disorder by Eli Lilly and Company, this one is the 8th largest by enrollment of the 19 interventional ones that give a count, is one of 5 that started in 2004, is one of 11 in phase 4, and was the 7th registered.
Eli Lilly and Company’s Bipolar Disorder studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 28 studies testing olanzapine in Bipolar Disorder, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 20 in Bipolar Disorder:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a randomized, parallel, open-label study of patients who have responded to treatment in the acute phase of their manic or mixed episode, with or without psychotic symptoms, with olanzapine in mono or co-therapy, and who are in syndromic and symptomatic remission at the time of enrollment into the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The main objective of this study is to compare the efficacy in the prevention of relapse to manic, depressive, or
mixed episodes in two groups of bipolar I patients
who responded to open-label treatment with olanzapine in mono or co-therapy and who are in symptomatic and syndromic remission at the time of entering the study.
The first group will receive olanzapine for a period of
3 months following inclusion into the study; the second group will receive olanzapine for 12 months.
Relapses will be evaluated in terms of the total YMRS
(Young Mania Rating Scale) and HAMD-21 (the 21-item Hamilton Depression Rating Scale) scores.
The secondary objectives posed by this study are the following:
To compare the efficacy of maintaining olanzapine for 3 months versus maintaining it for 12 months in
the improvement of symptomatology in patients who had achieved remission. To this end, the reductions
on the total YMRS score, YMRS specific non-psychotic
item scores, HAMD 21 total score, the scores on the
HAMD 21 specific mood-related items, the total and
positive scores on the BPRS (Brief Psychiatric Rating Scale), and the CGI BP S(Clinical Global Impression of Severity) with respect to baseline will be evaluated.
DSM IV TR criteria will be used for manic and
depressive episodes in order to assess syndromic improvement.
To compare the efficacy of long-term treatments by means of longitudinal assessment using the
general subscale of the CGI BP M (Clinical Global Impression - Modified) and proceeding to
intra- and intergroup analyses.
To evaluate the safety of maintenance treatment
with olanzapine and other coadjuvant medication
in both groups of follow up. To collect data
regarding treatment-derived adverse events,
changes in vital signs, laboratory analyses, and to measure the severity of possible extrapyramidal symptoms.
The Simpson Angus Scale, Barnes Akathisia Scale, and the Abnormal Involuntary Movement Scale (AIMS) will be used to assess the latter.
To determine the impact on resource utilization
the two treatment groups have. Direct costs derived
from hospital admissions, emergency room visits,
out-patient visits, home healthcare supports, as well as indirect costs derived from days out of work,
the patient's economic income, impact on the caregiver will also be quantified.
To assess the differences between groups
with respect to improvement in functioning and quality of life. The SF 36 Scale (the 36-Item Social Function Scale) will be applied.
To understand the degree of impact the illness provokes in relatives or caregivers
throughout the study. The self-report scale of
family burden (Escala de Carga Familiar - ECF) will be used for this purpose.
The record gives a start of Oct 2004 and a completion of Mar 2006. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2006. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olanzapine